|
SG11201401699WA
(en)
|
2011-11-11 |
2014-09-26 |
Rinat Neuroscience Corp |
Antibodies specific for trop-2 and their uses
|
|
EP2780039B9
(en)
|
2011-11-17 |
2018-04-18 |
Pfizer Inc |
Cytotoxic peptides and antibody drug conjugates thereof
|
|
CA2858806A1
(en)
*
|
2011-12-23 |
2013-06-27 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
EP3539982B1
(en)
|
2011-12-23 |
2025-02-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
EP2872894B1
(en)
*
|
2012-07-13 |
2019-04-17 |
Innate Pharma |
Screening of conjugated antibodies
|
|
WO2014047357A1
(en)
*
|
2012-09-21 |
2014-03-27 |
The Regents Of The University Of California |
Modified fc polypeptides, fc conjugates, and methods of use thereof
|
|
MX340090B
(es)
|
2012-11-05 |
2016-06-23 |
Pfizer |
Analogos de spliceostatina.
|
|
TW201726746A
(zh)
|
2012-11-07 |
2017-08-01 |
輝瑞股份有限公司 |
抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體
|
|
EP2916872B1
(en)
*
|
2012-11-09 |
2019-02-27 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
US10226535B2
(en)
|
2012-12-10 |
2019-03-12 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
|
US9789091B2
(en)
|
2013-03-14 |
2017-10-17 |
University Of Massachusetts |
Methods of inhibiting cataracts and presbyopia
|
|
HK1220626A1
(zh)
|
2013-03-15 |
2017-05-12 |
The Centre For Drug Research And Development |
具细胞毒性和抗有丝分裂的化合物以及其使用方法
|
|
US10611824B2
(en)
|
2013-03-15 |
2020-04-07 |
Innate Pharma |
Solid phase TGase-mediated conjugation of antibodies
|
|
FR3005051A1
(fr)
*
|
2013-04-25 |
2014-10-31 |
Pf Medicament |
Derives de la dolastatine 10 et d'auristatines
|
|
WO2014176696A1
(en)
|
2013-04-30 |
2014-11-06 |
Université de Montréal |
Novel biomarkers for acute myeloid leukemia
|
|
DK2991683T3
(da)
|
2013-05-02 |
2019-11-04 |
Glykos Finland Oy |
Konjugater af et glykoprotein eller en glykan med en toksisk ladning
|
|
BR112015030514A2
(pt)
|
2013-06-04 |
2017-08-29 |
Cytomx Therapeutics Inc |
Composições e métodos para conjugação de anticorpos ativáveis
|
|
WO2014202773A1
(en)
*
|
2013-06-20 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
KR20160042871A
(ko)
*
|
2013-06-21 |
2016-04-20 |
이나뜨 파르마, 에스.아. |
폴리펩티드의 효소적 콘쥬게이션
|
|
EP2818867A1
(en)
|
2013-06-27 |
2014-12-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies conjugated to at least one nucleic acid molecule and their use in multiplex immuno-detection assays
|
|
WO2015001082A1
(en)
|
2013-07-05 |
2015-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
|
KR20160040556A
(ko)
|
2013-07-11 |
2016-04-14 |
노파르티스 아게 |
미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형
|
|
US10195289B2
(en)
|
2013-07-31 |
2019-02-05 |
Rinat Neuroscience Corp. |
Engineered polypeptide conjugates using transglutaminase
|
|
MX371455B
(es)
|
2013-08-02 |
2020-01-28 |
Pfizer |
Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
|
|
RU2016119491A
(ru)
|
2013-11-04 |
2017-12-11 |
Пфайзер Инк. |
Конъюгаты антитела к efna4 с лекарственным средством
|
|
KR20160122127A
(ko)
*
|
2013-12-23 |
2016-10-21 |
자임워크스 인코포레이티드 |
C-말단의 경쇄 폴리펩타이드 연장부를 포함하는 항체 및 이의 컨쥬게이트 및 이들의 사용방법
|
|
JP6865584B2
(ja)
*
|
2013-12-23 |
2021-04-28 |
コヴァラブ |
化合物の共有結合性コンジュゲーションのためのｍＴＧ基質
|
|
KR102384740B1
(ko)
|
2013-12-27 |
2022-04-07 |
자임워크스 인코포레이티드 |
약물 접합체를 위한 설폰아마이드-함유 연결 시스템
|
|
SG11201605437YA
(en)
|
2014-01-27 |
2016-08-30 |
Pfizer |
Bifunctional cytotoxic agents
|
|
KR20190072663A
(ko)
|
2014-04-25 |
2019-06-25 |
리나트 뉴로사이언스 코프. |
약물이 고도로 로딩된 항체-약물 접합체
|
|
MA39909B1
(fr)
|
2014-04-25 |
2019-05-31 |
Pf Medicament |
Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
|
|
MX378281B
(es)
|
2014-04-25 |
2025-03-10 |
Pf Medicament |
Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
|
|
SMT202100146T1
(it)
|
2014-04-30 |
2021-05-07 |
Pfizer |
Coniugati di anticorpo anti-ptk7-farmaco
|
|
CA2951887A1
(en)
*
|
2014-06-12 |
2015-12-17 |
Cspc Dophen Corporation |
Homogenous antibody drug conjugates via enzymatic methods
|
|
US10973920B2
(en)
|
2014-06-30 |
2021-04-13 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
|
HUE049325T2
(hu)
*
|
2014-08-28 |
2020-09-28 |
Pfizer |
Stabilitás modulátor linker antitest-hatóanyag konjugátumokhoz történõ alkalmazásra
|
|
US11566082B2
(en)
|
2014-11-17 |
2023-01-31 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
|
EP3229836B1
(en)
|
2014-12-09 |
2019-11-13 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Human monoclonal antibodies against axl
|
|
ES2871624T3
(es)
|
2014-12-19 |
2021-10-29 |
Hoffmann La Roche |
Transglutaminasas microbianas, sustratos para las mismas y procedimientos para el uso de las mismas
|
|
CA2971246C
(en)
|
2014-12-19 |
2020-07-14 |
F. Hoffmann-La Roche Ag |
Identification of transglutaminase substrates and uses therefor
|
|
US11054425B2
(en)
|
2014-12-19 |
2021-07-06 |
Roche Sequencing Solutions, Inc. |
System and method for identification and characterization of transglutaminase species
|
|
ES2736106T3
(es)
*
|
2015-03-10 |
2019-12-26 |
Bristol Myers Squibb Co |
Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos
|
|
KR102046862B1
(ko)
|
2015-03-20 |
2019-11-20 |
화이자 인코포레이티드 |
Cti 약물작용발생단을 함유하는 이관능성 세포독성제
|
|
HUE057285T2
(hu)
|
2015-04-13 |
2022-04-28 |
Pfizer |
Terápiás ellenanyagok és alkalmazásaik
|
|
WO2016170447A1
(en)
|
2015-04-24 |
2016-10-27 |
Rinat Neuroscience Corp. |
Recombinant microbial transglutaminases
|
|
WO2017025179A1
(en)
|
2015-08-07 |
2017-02-16 |
Merck Patent Gmbh |
A transglutamine tag for efficient site-specific bioconjugation
|
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
|
PE20181070A1
(es)
|
2015-11-13 |
2018-07-04 |
Univ Massachusetts |
Moleculas bifuncionales que contienen peg para uso en la inhibicion de cataratas y presbicia
|
|
US10689458B2
(en)
|
2015-11-30 |
2020-06-23 |
Pfizer Inc. |
Site specific HER2 antibody drug conjugates
|
|
TWI812873B
(zh)
|
2015-11-30 |
2023-08-21 |
美商輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
|
KR102943992B1
(ko)
*
|
2015-12-15 |
2026-03-25 |
에프. 호프만-라 로슈 아게 |
트랜스글루타미나제 인식 부위를 갖는 fkbp 도메인
|
|
EP4032902A1
(en)
|
2015-12-18 |
2022-07-27 |
Eisai R&D Management Co., Ltd. |
C-terminal lysine conjugated immunoglobulins
|
|
US11103589B2
(en)
|
2016-01-08 |
2021-08-31 |
Apg Therapeutics, Inc. |
Polyethylenimine (PEI)-polypeptide conjugates and methods of use thereof
|
|
ES2904593T3
(es)
|
2016-01-21 |
2022-04-05 |
Pfizer |
Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
|
|
CA3012960A1
(en)
|
2016-02-01 |
2017-08-10 |
Pfizer Inc. |
Tubulysin analogs and methods for their preparation
|
|
EP3419670A2
(en)
|
2016-02-26 |
2019-01-02 |
Regeneron Pharmaceuticals, Inc. |
Optimized transglutaminase site-specific antibody conjugation
|
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
KR102438140B1
(ko)
|
2016-03-22 |
2022-08-31 |
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 |
인간화 항-클라우딘-1 항체 및 이의 용도
|
|
US10654887B2
(en)
|
2016-05-11 |
2020-05-19 |
Ge Healthcare Bio-Process R&D Ab |
Separation matrix
|
|
EP3455241B1
(en)
|
2016-05-11 |
2022-02-23 |
Cytiva BioProcess R&D AB |
Method of cleaning and/or sanitizing a separation matrix
|
|
US10703774B2
(en)
|
2016-09-30 |
2020-07-07 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
JP7122974B2
(ja)
|
2016-05-11 |
2022-08-22 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
変異免疫グロブリン結合ポリペプチド
|
|
JP7031934B2
(ja)
|
2016-05-11 |
2022-03-08 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックス
|
|
WO2017194592A1
(en)
|
2016-05-11 |
2017-11-16 |
Ge Healthcare Bioprocess R&D Ab |
Method of storing a separation matrix
|
|
US10730908B2
(en)
|
2016-05-11 |
2020-08-04 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
SG11201810470XA
(en)
|
2016-06-10 |
2018-12-28 |
Eisai R&D Man Co Ltd |
Lysine conjugated immunoglobulins
|
|
EP3272864A1
(en)
|
2016-07-20 |
2018-01-24 |
Paul Scherrer Institut |
Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
|
|
JP2018058822A
(ja)
|
2016-08-03 |
2018-04-12 |
ファイザー・インク |
ヘテロアリールスルホンをベースとするコンジュゲーションハンドル、これらの調製のための方法、および抗体薬物コンジュゲートの合成におけるこれらの使用
|
|
WO2018035391A1
(en)
|
2016-08-19 |
2018-02-22 |
Bristol-Myers Squibb Company |
Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
|
|
LT3512882T
(lt)
|
2016-09-14 |
2021-06-25 |
Merck Patent Gmbh |
Anti-c-met antikūnai ir jų antikūno-vaisto konjugatai, skirti efektyviam naviko slopinimui
|
|
US12448411B2
(en)
|
2016-09-30 |
2025-10-21 |
Cytiva Bioprocess R&D Ab |
Separation method
|
|
IL310865A
(en)
*
|
2016-10-17 |
2024-04-01 |
Pfizer |
Antibodies against EDB and antibody-drug conjugates
|
|
US10398783B2
(en)
|
2016-10-20 |
2019-09-03 |
Bristol-Myers Squibb Company |
Antiproliferative compounds and conjugates made therefrom
|
|
CN110121508A
(zh)
|
2016-10-25 |
2019-08-13 |
法国国家健康和医学研究院 |
与cd160跨膜同种型结合的单克隆抗体
|
|
US20210277145A1
(en)
|
2016-11-17 |
2021-09-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for increasing endogenous protein level
|
|
EP3573995A1
(en)
|
2017-01-24 |
2019-12-04 |
Pfizer Inc. |
Calicheamicin derivatives and antibody drug conjugates thereof
|
|
WO2018141959A1
(en)
|
2017-02-06 |
2018-08-09 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
|
EP3579872A1
(en)
|
2017-02-10 |
2019-12-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
|
US11274160B2
(en)
|
2017-03-02 |
2022-03-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to Nectin-4 and uses thereof
|
|
US11198735B2
(en)
|
2017-03-03 |
2021-12-14 |
Rinat Neuroscience Corp. |
Anti-GITR antibodies and methods of use thereof
|
|
BR112019021520A2
(pt)
|
2017-04-14 |
2020-08-04 |
Tollnine, Inc. |
oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
|
|
WO2018213335A1
(en)
|
2017-05-16 |
2018-11-22 |
Scalmibio, Inc. |
Activatable antibodies and methods of use thereof
|
|
JP7234142B2
(ja)
|
2017-06-02 |
2023-03-07 |
ファイザー・インク |
Ｆｌｔ３に特異的な抗体およびその使用
|
|
US10487084B2
(en)
|
2017-08-16 |
2019-11-26 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
|
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
|
US10494370B2
(en)
|
2017-08-16 |
2019-12-03 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
|
|
US10457681B2
(en)
|
2017-08-16 |
2019-10-29 |
Bristol_Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
|
|
US10472361B2
(en)
|
2017-08-16 |
2019-11-12 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
|
|
AU2018337671B2
(en)
*
|
2017-09-19 |
2021-03-04 |
Paul Scherrer Institut |
Transglutaminase conjugation method and linker
|
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
|
WO2019082020A1
(en)
*
|
2017-10-27 |
2019-05-02 |
Pfizer Inc. |
ANTIBODIES AND CONJUGATES CD123-SPECIFIC ANTIBODIES AND USES THEREOF
|
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
|
MX2020008183A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Anticuerpos especificos para cd70 y sus usos.
|
|
MX2020008184A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Receptores de antigeno quimericos dirigidos a cd70.
|
|
TW202430218A
(zh)
|
2018-02-27 |
2024-08-01 |
美商輝瑞大藥廠 |
抗體純化
|
|
WO2019175380A2
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
US20210023209A1
(en)
|
2018-03-16 |
2021-01-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
EP3765053A2
(en)
|
2018-03-16 |
2021-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
WO2019180150A1
(en)
|
2018-03-22 |
2019-09-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
|
|
WO2019209811A1
(en)
|
2018-04-24 |
2019-10-31 |
Bristol-Myers Squibb Company |
Macrocyclic toll-like receptor 7 (tlr7) agonists
|
|
US11525010B2
(en)
|
2018-05-23 |
2022-12-13 |
Pfizer Inc. |
Antibodies specific for GUCY2c and uses thereof
|
|
AU2019274654B2
(en)
|
2018-05-23 |
2023-07-20 |
Pfizer Inc. |
Antibodies specific for CD3 and uses thereof
|
|
JP7458997B2
(ja)
|
2018-05-29 |
2024-04-01 |
ブリストル－マイヤーズ スクイブ カンパニー |
プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法
|
|
BR112020025287A2
(pt)
|
2018-06-25 |
2021-03-09 |
University Of Washington |
Projeto de novo de miméticos de interleucina potentes e seletivos
|
|
US11554120B2
(en)
|
2018-08-03 |
2023-01-17 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
|
|
WO2020058372A1
(en)
|
2018-09-19 |
2020-03-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
US20220025058A1
(en)
|
2018-11-06 |
2022-01-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
|
JP2022511390A
(ja)
|
2018-11-20 |
2022-01-31 |
ユニバーシティ オブ ワシントン |
分割インターロイキン模倣体およびその使用
|
|
DK3886914T3
(da)
|
2018-11-30 |
2023-07-03 |
Bristol Myers Squibb Co |
Antistof omfattende en glutaminholdig letkæde-c-terminal forlængelse, konjugater deraf og fremgangsmåder samt anvendelser
|
|
WO2020123425A2
(en)
*
|
2018-12-12 |
2020-06-18 |
Bristol-Myers Squibb Company |
Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
|
|
EP3894543A1
(en)
|
2018-12-14 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs
|
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
|
TWI851634B
(zh)
|
2018-12-21 |
2024-08-11 |
大陸商沐特圖公司 |
Muc18特異性抗體
|
|
EP3908608A1
(en)
*
|
2019-01-09 |
2021-11-17 |
Vect-Horus |
Transferrin receptor-binding molecules, conjugates thereof and their uses
|
|
CN113613679A
(zh)
*
|
2019-03-19 |
2021-11-05 |
保罗·谢勒学院 |
基于甘氨酸的接头的转谷氨酰胺酶缀合方法
|
|
CN114630838A
(zh)
|
2019-05-20 |
2022-06-14 |
法国国家健康和医学研究院 |
新的抗cd25抗体
|
|
EP3980423A1
(en)
|
2019-06-10 |
2022-04-13 |
Sutro Biopharma, Inc. |
5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
|
|
EP3980080A1
(en)
*
|
2019-06-10 |
2022-04-13 |
Sutro Biopharma, Inc. |
Immunomodulator antibody drug conjugates and uses thereof
|
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
EP4069311A1
(en)
*
|
2019-12-03 |
2022-10-12 |
Debiopharm Research & Manufacturing SA |
Reactive conjugates
|
|
EP4072682A1
(en)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antibodies having specificity to her4 and uses thereof
|
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
|
EP4149558A1
(en)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
|
AU2021275489A1
(en)
|
2020-05-20 |
2022-12-01 |
Centre National De La Recherche Scientifique - Cnrs - |
Single domain antibodies and their use in cancer therapies
|
|
CA3184802A1
(en)
|
2020-05-26 |
2021-12-02 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
|
|
MX2023000662A
(es)
|
2020-07-17 |
2023-02-27 |
Pfizer |
Anticuerpos terapeuticos y sus usos.
|
|
EP4189071A1
(en)
|
2020-08-03 |
2023-06-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
|
CN112062855B
(zh)
|
2020-08-26 |
2024-08-30 |
北京天诺健成医药科技有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
|
JP2023542295A
(ja)
|
2020-09-14 |
2023-10-06 |
リジェネロン ファーマシューティカルズ，インク． |
Ｇｌｐ１ペプチド模倣薬を含む抗体薬物複合体及びその使用
|
|
EP4213886A1
(en)
|
2020-09-18 |
2023-07-26 |
Araris Biotech AG |
Transglutaminase conjugation method with amino acid-based linkers
|
|
US20230365979A1
(en)
*
|
2020-09-29 |
2023-11-16 |
Idemitsu Kosan Co.,Ltd. |
Peptide tag and tagged protein including same
|
|
US11866502B2
(en)
|
2020-10-22 |
2024-01-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-FGFR2 antibodies and methods of use thereof
|
|
JP7789396B2
(ja)
|
2020-10-25 |
2025-12-22 |
アラリス バイオテック アーゲー |
抗体－リンカーコンジュゲートを生成するための手段および方法
|
|
MX2023004935A
(es)
|
2020-11-10 |
2023-07-07 |
Regeneron Pharma |
Conjugados de anticuerpos y selenio.
|
|
JP2023554587A
(ja)
|
2020-11-12 |
2023-12-28 |
アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） |
Ｓａｒｓ－ｃｏｖ－２ スパイクタンパク質の受容体結合ドメインにコンジュゲートまたは融合している抗体およびワクチン目的でのそれらの使用
|
|
CN118878693A
(zh)
|
2020-11-23 |
2024-11-01 |
康诺亚生物医药科技（成都）有限公司 |
一种双特异性抗体及其用途
|
|
CN114573702A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技（成都）有限公司 |
一种新型肿瘤衔接器治疗药物的开发和应用
|
|
CN114573703A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技（成都）有限公司 |
一种t细胞衔接器治疗剂的开发和应用
|
|
US20240131138A1
(en)
|
2020-12-23 |
2024-04-25 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
|
|
CN114685657B
(zh)
|
2020-12-31 |
2024-08-16 |
康诺亚生物医药科技（成都）有限公司 |
一种功能增强型抗体阻断剂的开发及其应用
|
|
MX2023008986A
(es)
|
2021-01-29 |
2023-08-15 |
Inst Nat Sante Rech Med |
Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna.
|
|
EP4297798A4
(en)
*
|
2021-02-25 |
2025-11-12 |
Allygen Group |
Targeting Conjugates Comprising Effector Molecules and Their Uses
|
|
FR3120865B1
(fr)
|
2021-03-19 |
2025-02-28 |
Univ Toulouse 3 Paul Sabatier |
Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations
|
|
FR3120866B1
(fr)
|
2021-03-19 |
2025-02-28 |
Univ Toulouse 3 Paul Sabatier |
Molécule hybride comprenant un peptide citrulliné dérivé de la fibrine et un anticorps ou fragment d’anticorps se liant à CD38 et/ou CD138, et ses utilisations
|
|
FR3120877B1
(fr)
|
2021-03-19 |
2025-03-14 |
Univ Toulouse 3 Paul Sabatier |
Cellule immunitaire comprenant un récepteur Fc à sa surface, et sur lequel est greffé une molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations
|
|
KR20240012352A
(ko)
|
2021-03-23 |
2024-01-29 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
T 세포 림프종의 진단 및 치료 방법
|
|
CN117321087A
(zh)
|
2021-03-26 |
2023-12-29 |
先天制药公司 |
包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
|
|
EP4320153A1
(en)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
|
US20240368605A1
(en)
|
2021-04-19 |
2024-11-07 |
Institut National de la Santé et de la Recherche Médicale |
Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2
|
|
US20250281633A1
(en)
|
2021-05-03 |
2025-09-11 |
Merck Patent Gmbh |
Her2 targeting fc antigen binding fragment-drug conjugates
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
CN117616050A
(zh)
|
2021-06-09 |
2024-02-27 |
先天制药公司 |
与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
WO2022263451A1
(en)
|
2021-06-15 |
2022-12-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Peptides derived from the spike protein of sars-cov-2 and uses thereof for diagnosis and vaccine purposes
|
|
KR20240038928A
(ko)
|
2021-07-28 |
2024-03-26 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질-항바이러스 화합물 접합체
|
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
|
EP4422695A1
(en)
|
2021-10-25 |
2024-09-04 |
Araris Biotech AG |
Methods for producing antibody-linker conjugates
|
|
JP2024540505A
(ja)
|
2021-11-17 |
2024-10-31 |
アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル |
ユニバーサルサルベコウイルスワクチン
|
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
|
EP4201956A1
(en)
*
|
2021-12-23 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Kutzneria albida (kalbtg) transglutaminase used for antibody conjugations
|
|
MX2024008361A
(es)
|
2022-01-14 |
2024-09-10 |
Regeneron Pharma |
Derivados de verrucarina a y conjugados anticuerpo-fármaco de los mismos.
|
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
|
KR20240150807A
(ko)
|
2022-02-22 |
2024-10-16 |
아라리스 바이오테크 아게 |
2개 이상의 페이로드를 포함하는 펩티드 링커
|
|
IL315262A
(en)
|
2022-03-03 |
2024-10-01 |
Pfizer |
Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses
|
|
CA3243669A1
(en)
|
2022-03-11 |
2023-09-14 |
Regeneron Pharmaceuticals, Inc. |
ANTI-GLP1R ANTIBODY-DRUG CONJUGATES INCLUDING GLP1 PEPTIDOMIMETS AND THEIR USES
|
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
|
WO2023227660A1
(en)
|
2022-05-25 |
2023-11-30 |
Innate Pharma |
Nectin-4 binding agents
|
|
US20230408497A1
(en)
|
2022-06-20 |
2023-12-21 |
Sysmex Corporation |
Labeled polypeptide, modified polypeptide, production method for these polypeptides, reagent containing these polypeptides, and measurement method for target substance
|
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
|
US20260029402A1
(en)
|
2022-07-22 |
2026-01-29 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
|
CN120659627A
(zh)
|
2022-07-29 |
2025-09-16 |
瑞泽恩制药公司 |
用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
|
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
|
EP4584291A1
(en)
|
2022-09-08 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
|
FR3139820B1
(fr)
|
2022-09-15 |
2025-12-12 |
Univ Toulouse Iii – Paul Sabatier |
Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une vascularite auto-immune, et ses utilisations
|
|
FR3139821B1
(fr)
|
2022-09-15 |
2025-12-12 |
Univ Toulouse Iii – Paul Sabatier |
Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une dermatite auto-immune, et ses utilisations
|
|
CN119948059A
(zh)
|
2022-10-05 |
2025-05-06 |
法国国家健康医学研究院 |
靶向dc的抗尼帕病毒感染疫苗
|
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
|
AU2023379457A1
(en)
|
2022-11-14 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
EP4626553A2
(en)
|
2022-11-30 |
2025-10-08 |
Regeneron Pharmaceuticals, Inc. |
Tlr7 agonists and antibody-drug-conjugates thereof
|
|
WO2024170543A1
(en)
|
2023-02-14 |
2024-08-22 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cd44 antibodies and uses thereof
|
|
WO2024236156A1
(en)
|
2023-05-17 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cathepsin-d antibodies
|
|
WO2024240162A1
(en)
|
2023-05-23 |
2024-11-28 |
Shanghai Allygen Biologics Co., Ltd. |
Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
|
|
IL325400A
(en)
|
2023-07-10 |
2026-02-01 |
Regeneron Pharma |
Anti-human CACNG1 antibody-drug conjugates and their uses
|
|
WO2025082990A1
(en)
|
2023-10-15 |
2025-04-24 |
Araris Biotech Ag |
Antibody-drug conjugates using two different types of topoisomerase i inhibitors
|
|
CN122295135A
(zh)
|
2023-11-03 |
2026-06-26 |
瑞泽恩制药公司 |
作为glp1r激动剂的肽酸及其抗体-药物缀合物
|
|
WO2025117727A1
(en)
|
2023-11-29 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
|
|
WO2025120015A1
(en)
|
2023-12-06 |
2025-06-12 |
Institut National de la Santé et de la Recherche Médicale |
Cd5 targeting antibodies with depleting and t or b-cell activation effects
|
|
US20250282776A1
(en)
|
2024-03-05 |
2025-09-11 |
Bristol-Myers Squibb Company |
Bicyclic TLR7 Agonists and Uses Thereof
|
|
WO2025188694A1
(en)
|
2024-03-05 |
2025-09-12 |
Bristol-Myers Squibb Company |
Tricyclic tlr7 agonists and uses thereof
|
|
EP4624494A1
(en)
|
2024-03-29 |
2025-10-01 |
Institut Curie |
Her2 single domain antibody and uses thereof
|
|
WO2025224297A1
(en)
|
2024-04-26 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to tgfbi and uses thereof
|
|
WO2025238052A1
(en)
|
2024-05-15 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
|
|
WO2026013234A1
(en)
|
2024-07-10 |
2026-01-15 |
Araris Biotech Ag |
Triple-payload antibody-drug conjugates (adcs)
|